Developing new methods for creating cancer-fighting drugs
New Catalysts and Strategies for Selective C–H Functionalization and Cycloaddition Reactions
['FUNDING_OTHER'] · UNIVERSITY OF VIRGINIA · NIH-10904658
This study is exploring new ways to create small molecules that could become better cancer treatments, making it easier to find effective medications for patients who need them.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-10904658 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the processes used to create small molecules that can be developed into new drugs, particularly for cancer treatment. The team is working on innovative methods to selectively modify chemical compounds, which can lead to more effective therapies. By overcoming current limitations in organic synthesis, they aim to accelerate the discovery of new medications that address unmet medical needs. The research involves collaboration with other projects to apply these new compounds to target biological processes relevant to cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancer or those at risk of developing cancer who may benefit from new therapeutic options.
Not a fit: Patients with conditions unrelated to cancer or those who are not seeking new treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments through improved drug synthesis methods.
How similar studies have performed: Other research in the field of organic synthesis and drug discovery has shown promise, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HILINSKI, MICHAEL KENNETH — UNIVERSITY OF VIRGINIA
- Study coordinator: HILINSKI, MICHAEL KENNETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment